|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SZRD1 |
Gene summary for SZRD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SZRD1 | Gene ID | 26099 |
| Gene name | SUZ RNA binding domain containing 1 | |
| Gene Alias | C1orf144 | |
| Cytomap | 1p36.13 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q7Z422 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26099 | SZRD1 | P126T-E | Human | Esophagus | ESCC | 1.42e-05 | 8.17e-01 | 0.1125 |
| 26099 | SZRD1 | P127T-E | Human | Esophagus | ESCC | 2.90e-22 | 4.75e-01 | 0.0826 |
| 26099 | SZRD1 | P128T-E | Human | Esophagus | ESCC | 9.91e-25 | 9.70e-01 | 0.1241 |
| 26099 | SZRD1 | P130T-E | Human | Esophagus | ESCC | 8.01e-68 | 1.54e+00 | 0.1676 |
| 26099 | SZRD1 | HCC1_Meng | Human | Liver | HCC | 2.53e-50 | -1.99e-02 | 0.0246 |
| 26099 | SZRD1 | HCC2_Meng | Human | Liver | HCC | 1.56e-10 | -5.63e-02 | 0.0107 |
| 26099 | SZRD1 | cirrhotic2 | Human | Liver | Cirrhotic | 1.23e-05 | 1.05e-01 | 0.0201 |
| 26099 | SZRD1 | cirrhotic3 | Human | Liver | Cirrhotic | 8.76e-03 | 9.85e-02 | 0.0215 |
| 26099 | SZRD1 | HCC1 | Human | Liver | HCC | 3.65e-02 | 3.23e+00 | 0.5336 |
| 26099 | SZRD1 | HCC2 | Human | Liver | HCC | 3.35e-10 | 3.17e+00 | 0.5341 |
| 26099 | SZRD1 | Pt13.b | Human | Liver | HCC | 7.17e-06 | 1.38e-01 | 0.0251 |
| 26099 | SZRD1 | S014 | Human | Liver | HCC | 4.36e-20 | 8.32e-01 | 0.2254 |
| 26099 | SZRD1 | S015 | Human | Liver | HCC | 3.98e-17 | 9.63e-01 | 0.2375 |
| 26099 | SZRD1 | S016 | Human | Liver | HCC | 1.59e-19 | 9.46e-01 | 0.2243 |
| 26099 | SZRD1 | S027 | Human | Liver | HCC | 6.58e-12 | 1.23e+00 | 0.2446 |
| 26099 | SZRD1 | S028 | Human | Liver | HCC | 7.49e-25 | 1.42e+00 | 0.2503 |
| 26099 | SZRD1 | S029 | Human | Liver | HCC | 4.83e-25 | 1.38e+00 | 0.2581 |
| 26099 | SZRD1 | C04 | Human | Oral cavity | OSCC | 9.56e-28 | 1.43e+00 | 0.2633 |
| 26099 | SZRD1 | C21 | Human | Oral cavity | OSCC | 8.36e-78 | 2.38e+00 | 0.2678 |
| 26099 | SZRD1 | C30 | Human | Oral cavity | OSCC | 2.47e-55 | 2.56e+00 | 0.3055 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SZRD1 | SNV | Missense_Mutation | c.200N>T | p.Thr67Ile | p.T67I | Q7Z422 | protein_coding | deleterious(0) | benign(0.179) | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SZRD1 | SNV | Missense_Mutation | novel | c.422N>A | p.Gly141Asp | p.G141D | Q7Z422 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| SZRD1 | SNV | Missense_Mutation | c.192N>C | p.Lys64Asn | p.K64N | Q7Z422 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
| SZRD1 | insertion | Frame_Shift_Ins | novel | c.163_164insCCTTCTCAGCCTCTTTCTTCTCTCTGCTTTTCTCTAAAAT | p.Gly55AlafsTer93 | p.G55Afs*93 | Q7Z422 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| SZRD1 | SNV | Missense_Mutation | novel | c.325N>A | p.Glu109Lys | p.E109K | Q7Z422 | protein_coding | deleterious(0) | benign(0.153) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SZRD1 | insertion | Frame_Shift_Ins | novel | c.60_61insA | p.Arg21LysfsTer31 | p.R21Kfs*31 | Q7Z422 | protein_coding | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | ||
| SZRD1 | SNV | Missense_Mutation | rs374656978 | c.452N>A | p.Arg151His | p.R151H | Q7Z422 | protein_coding | tolerated(0.35) | possibly_damaging(0.886) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| SZRD1 | SNV | Missense_Mutation | novel | c.302N>A | p.Arg101Gln | p.R101Q | Q7Z422 | protein_coding | deleterious(0.05) | probably_damaging(0.988) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SZRD1 | SNV | Missense_Mutation | rs374656978 | c.452G>A | p.Arg151His | p.R151H | Q7Z422 | protein_coding | tolerated(0.35) | possibly_damaging(0.886) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SZRD1 | SNV | Missense_Mutation | c.65N>A | p.Arg22Gln | p.R22Q | Q7Z422 | protein_coding | tolerated(0.12) | probably_damaging(0.953) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |